Urogen Pharma Ltd. (NASDAQ: URGN) saw its stock plummet 9.37% in pre-market trading, following the release of its third-quarter 2025 financial results. The biopharmaceutical company reported quarterly sales of $27.5 million, falling short of analyst expectations of $33.093 million by 16.90%.

While Urogen's Q3 earnings per share (EPS) of $(0.69) met analyst consensus estimates, investors appeared more concerned with the revenue miss and the company's declining cash position. As of September 30, 2025, Urogen's cash, cash equivalents, and marketable securities totaled $127.4 million, a significant decrease from $241.7 million at the end of 2024. This drop in liquid assets, coupled with a total shareholders' deficit of $115.4 million, may be raising concerns about the company's financial stability.

Despite some positive developments, such as JELMYTO's 13% year-over-year growth in underlying demand revenue and the FDA's agreement to submit a New Drug Application for UGN-103, the overall financial picture seems to have spooked investors. The company's full-year 2025 operating expense guidance of $215 to $225 million, combined with the revenue miss, suggests ongoing challenges in achieving profitability, likely contributing to the sharp pre-market decline.